Drug maker Cipla taped an increase in its net earnings for the September quarter duration of 2021-22Drug manufacturer Cipla on Tuesday taped a 7.6 percent increase in its consolidated net revenue for the September quarter of existing fiscal, as it stood at Rs 712 crore, against Rs 661.8 crore in the matching duration of last year.The company's EBITDA or earnings prior to interest, tax, depreciation and amortisation likewise went up by 4.2 per cent to Rs 1,226.2 crore against Rs 1,176.7 crore recorded in the corresponding duration of last year.
Cipla's consolidated earnings from operations increased by 9.6 percent to Rs 5,519.8 crore during the July-September quarter of 2021-22 from Rs 5,038.3 crore in the matching quarter of 2020-21.
I am pleased to see the strong momentum in core treatments throughout our branded markets and sustained cost control causing 10 percent revenue development and 22.2 percent EBITDA margin for the quarter, offsetting rate erosion and normalising covid contribution.
In India, we continue to drive strong performance led by continual volume traction regardless of a high FY21 base, said Cipla's managing director and international CEO Umang Vohra, while commenting on the outcomes.